SIMD 2022 Infographic: Advancing the diagnosis and management of a rare neurometabolic disorder: A focus on AADC deficiency
View our infographic, distributed at the PTC Therapeutics symposium at the 2022 SIMD Annual Meeting, which introduces aromatic L-amino acid decarboxylase (AADC) deficiency, describes the key signs and symptoms of the condition, and outlines the tests required for diagnosis
Find out more about the signs and symptoms of AADC deficiency that may raise clinical suspicion and warrant further testing
Learn more about the preliminary tests which may be used to screen for AADC deficiency, and the core diagnostic tests needed to obtain definitive confirmation of the condition
Understand the importance of securing an early and accurate diagnosis for patients with AADC deficiency
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-AADC-2200063 I July 2022
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.